Point72 Hong Kong’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-11,083
| Closed | -$1.39M | – | 470 |
|
|
2025
Q2 | $1.39M | Buy |
11,083
+7,203
| +186% | +$898K | 0.09% | 181 |
|
|
2025
Q1 | $531K | Sell |
3,880
-22,299
| -85% | -$3.19M | 0.03% | 249 |
|
|
2024
Q4 | $4M | Buy |
+26,179
| New | +$4.42M | 0.24% | 89 |
|
|
2024
Q2 | – | Sell |
-5,902
| Closed | -$1.27M | – | 463 |
|
|
2024
Q1 | $1.27M | Buy |
+5,902
| New | +$1.38M | 0.06% | 242 |
|
|
2022
Q4 | – | Sell |
-6,022
| Closed | -$1.61M | – | 253 |
|
|
2022
Q3 | $1.61M | Sell |
6,022
-9,074
| -60% | -$1.93M | 0.06% | 415 |
|
|
2022
Q2 | $3.08M | Buy |
15,096
+4,999
| +50% | +$1.02M | 0.11% | 232 |
|
|
2022
Q1 | $2.13M | Buy |
10,097
+9,758
| +2,878% | +$2.12M | 0.07% | 309 |
|
|
2021
Q4 | $81K | Sell |
339
-22,020
| -98% | -$5.66M | ﹤0.01% | 1233 |
|
|
2021
Q3 | $6.33M | Buy |
22,359
+6,679
| +43% | +$2.19M | 0.21% | 81 |
|
|
2021
Q2 | $5.43M | Buy |
+15,680
| New | +$4.75M | 0.18% | 100 |
|
|
2021
Q1 | – | Sell |
-1,840
| Closed | -$451K | – | 1812 |
|
|
2020
Q4 | $451K | Buy |
+1,840
| New | +$475K | 0.02% | 733 |
|
|
2020
Q3 | – | Sell |
-7,699
| Closed | -$2.06M | – | 1204 |
|
|
2020
Q2 | $2.06M | Buy |
7,699
+7,079
| +1,142% | +$2.13M | 0.23% | 109 |
|
|
2020
Q1 | $196K | Sell |
620
-724
| -54% | -$220K | 0.09% | 94 |
|
|
2019
Q4 | $399K | Buy |
1,344
+1,099
| +449% | +$305K | 0.09% | 181 |
|
|
2019
Q3 | $57K | Buy |
+245
| New | +$57K | 0.02% | 558 |
|
|
2019
Q2 | – | Sell |
-127
| Closed | -$30K | – | 1126 |
|
|
2019
Q1 | $30K | Buy |
+127
| New | +$40K | 0.01% | 624 |
|
|
2018
Q3 | – | Sell |
-90
| Closed | -$26K | – | 902 |
|
|
2018
Q2 | $26K | Sell |
90
-293
| -77% | -$82.4K | 0.01% | 537 |
|
|
2018
Q1 | $105K | Buy |
+383
| New | +$119K | 0.05% | 311 |
|
|
2017
Q4 | – | Sell |
-97
| Closed | -$30K | – | 850 |
|
|
2017
Q3 | $30K | Sell |
97
-484
| -83% | -$143K | 0.02% | 330 |
|
|
2017
Q2 | $158K | Buy |
+581
| New | +$154K | 0.16% | 51 |
|
|
2017
Q1 | – | Sell |
-7,730
| Closed | -$2.19M | – | 742 |
|
|
2016
Q4 | $2.19M | Buy |
+7,730
| New | +$2.29M | 2.19% | 2 |
|
|
2016
Q3 | – | Sell |
-7,346
| Closed | -$1.78M | – | 737 |
|
|
2016
Q2 | $1.78M | Buy |
+7,346
| New | +$1.94M | 2.06% | 6 |
|
|
2016
Q1 | – | Sell |
-100
| Closed | -$31K | – | 512 |
|
|
2015
Q4 | $31K | Buy |
+100
| New | +$28.7K | 0.1% | 172 |
|
|
2015
Q2 | – | Sell |
-820
| Closed | -$346K | – | 182 |
|
|
2015
Q1 | $346K | Buy |
820
+654
| +394% | +$258K | 0.31% | 36 |
|
|
2014
Q4 | $56K | Buy |
+166
| New | +$53.7K | 0.06% | 383 |
|
Other funds holding BIIB
Point72 Hong Kong's BIIB Position: Q3 2025 in Review
Point72 Hong Kong sold out of Biogen (BIIB) in Q3 2025, closing a stake of 11,083 shares — an estimated $1.39M sold.
Point72 Hong Kong first reported a position in BIIB in Q4 2014 and held it in 25 quarters. The position peaked at $6.33M in Q3 2021. 906 funds tracked by Wall St. Rank hold BIIB as of Q3 2025.
- Point72 Hong Kong reported no remaining Biogen position as of Q3 2025 after selling out during the quarter.
- Point72 Hong Kong sold 11,083 Biogen shares in Q3 2025, an estimated $1.39M.
- Point72 Hong Kong first reported a position in Biogen in Q4 2014 and held it in 25 quarters.
- Point72 Hong Kong's Biogen position peaked at $6.33M in Q3 2021.
- 906 funds tracked by Wall St. Rank held Biogen as of Q3 2025.
Based on Point72 Hong Kong's 13F filing for Q3 2025, filed 14 Nov 2025.